文献类型：期刊文献

英文题名：Identified biosynthetic pathway of aspergiolide A and a novel strategy to increase its production in a marine-derived fungus Aspergillus glaucus by feeding of biosynthetic precursors and inhibitors simultaneously

作者：Sun, Xueqian[1];Zhou, Xiangshan[1];Cai, Menghao[1];Tao, Kejing[1];Zhang, Yuanxing[1]

机构：[1]E China Univ Sci & Technol, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China

年份：2009

卷号：100

期号：18

起止页码：4244

外文期刊名：BIORESOURCE TECHNOLOGY

收录：;WOS:【SCI-EXPANDED(收录号:WOS:000266964400028)】；

基金：This work was financially supported by the Chinese National High Technology Research and Development Program (No. 2006AA09Z429) and Shanghai Leading Academic Discipline Project (Project Number: B505).

语种：英文

外文关键词：Aspergillus glaucus; Aspergiolide A; Pathway specific inhibitor; Polyketide pathway; Precursor

摘要：Aspergiolide A is a novel anti-tumor anthraquinone derivant produced by marine-derived fungus Aspergillus glaucus. To identify its biosynthetic pathway and further improve the production, the effects of biosynthetic pathway specific inhibitors and precursors were investigated. Cerulenin and iodoacetamide, the specific inhibitors of polyketide pathway, could completely inhibit the aspergiolide A accumulation. Putative precursors of polyketide pathway could increase aspergiolide A production greatly, such as 6 mM acetate increased production by 135%. Simvastatin and citrate, the inhibitors of mevalonate pathway, stimulated the production by 63% and 179%, respectively. Considering that acetyl-CoA is the common starter unit in both polyketide and mevalonate pathway, a novel strategy was designed to stimulate the aspergiolide A accumulation. Combinations of 12 mM acetate with 0.3 mM simvastatin could increase the production by 151%, while the supplementation with 12 mM acetate and 12 mM citrate brought a 262% increase of aspergiolide A production. The strategy might be very useful to enhance the production of other secondary metabolites derived from polyketide pathway. (C) 2009 Elsevier Ltd. All rights reserved.